Sotera Medical Raises Additional Funding

Sotera MedicalSotera Medical Corp., a Cleveland, OH-based company developing a novel device for use in cardiac procedures to treat atrial fibrillation, added Valley Growth Ventures to its seed funding round. 

The amount of the deal was not disclosed.

With this investment, VGV – a fund based in Youngstown, Ohio, that supports high-growth, early-stage companies across the state, with a preference for those in Northeast Ohio – joins other seed round investors including JumpStart Inc., North Coast Angel Fund, Northwest Ohio Tech Fund II managed by ProMedica Ventures, private investors, and the State of Ohio.

The company intends to use the funds to continue to develop its device to achieve its first clinical milestone in 2019.

Led by William Fuller, CEO and co-founder, Sotera is advancing a device that addresses an important unmet clinical need in the treatment of atrial fibrillation (AF), an irregular heartbeat that, if left untreated, can lead to blood clots, stroke, or heart failure. AF is often treated with a procedure called catheter ablation, which is not without risk to the esophagus.
To address this risk, Dr. Emile Daoud, co-founder of Sotera and director of electrophysiology and professor of clinical medicine at The Ohio State University Wexner Medical Center — along with a team of physicians — developed a device to better protect the esophagus during catheter ablation.



Join the discussion